Penobscot Investment Management’s Teva Pharmaceuticals TEVA Stock Holding History

Penobscot Investment Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-6,530	Closed	-$300K	–	189
2016 Q3	$300K	Sell	6,530 -300	-4%	-$15.7K	0.11%	148
2016 Q2	$343K	Sell	6,830 -80	-1%	-$4.26K	0.12%	140
2016 Q1	$370K	Hold	6,910	–	–	0.14%	131
2015 Q4	$454K	Hold	6,910	–	–	0.14%	122
2015 Q3	$390K	Sell	6,910 -460	-6%	-$29.8K	0.13%	137
2015 Q2	$436K	Hold	7,370	–	–	0.14%	137
2015 Q1	$459K	Hold	7,370	–	–	0.15%	131
2014 Q4	$424K	Hold	7,370	–	–	0.13%	131
2014 Q3	$396K	Sell	7,370 -100	-1%	-$5.3K	0.13%	126
2014 Q2	$392K	Buy	7,470 +1,900	+34%	+$97.1K	0.13%	127
2014 Q1	$294K	Sell	5,570 -140	-2%	-$6.47K	0.1%	142
2013 Q4	$229K	Sell	5,710 -1,430	-20%	-$56.3K	0.08%	157
2013 Q3	$270K	Hold	7,140	–	–	0.11%	140
2013 Q2	$280K	Buy	+7,140	New	+$278K	0.12%	128

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

Penobscot Investment Management's TEVA Position: Q4 2016 in Review

Penobscot Investment Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 6,530 shares — an estimated $300K sold.

Penobscot Investment Management first reported a position in TEVA in Q2 2013 and held it in 14 quarters. The position peaked at $459K in Q1 2015. 738 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

Penobscot Investment Management reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Penobscot Investment Management sold 6,530 Teva Pharmaceuticals shares in Q4 2016, an estimated $300K.
Penobscot Investment Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 14 quarters.
Penobscot Investment Management's Teva Pharmaceuticals position peaked at $459K in Q1 2015.
738 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Penobscot Investment Management's 13F filing for Q4 2016, filed 13 Feb 2017.